Obiettivo Razoxane 5ICRF-159) has been shown to have clear dose dependent efficacy in treatment of patients with psoriasis refractory to other conventional therapies. In an attempt to improve the therapeutic index of Razoxane, i.e. maintening high efficacy and lowering the dose-limiting neutropenia, its detrox-enantiomereICRF-187 has been developed. It is known that doses up till 1/3 of MTD (maximum treatment dose) do not cause any significant drop in peripheral leukocyte counts. This project has been designed to determine the following:1. Confirmation of the efficacy and safety of i.v. administered, commercially available ICRF-187 (trademark CARDIOXANE in EU, ZINECARD in USA and CAN)2. Development of a new drug formulation: cream or ointment for topical treatment of skin lesions.3. Detailed study of pre-clinical and clinical efficacy of new formulation4. Development of pharmacological, toxicological and clinical documentation necessary to support registration in EU countries. Programma(i) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Argomento(i) 1.1.1.-7. - Chronic and degenerative diseases, cancer, diabetes, cardivascular diseases and rare diseases Invito a presentare proposte Data not available Meccanismo di finanziamento EAW - Exploratory awards Coordinatore CSC PHARMACEUTICALS HANDELSGES. MBH Contributo UE Nessun dato Indirizzo Heiligenstaederstrasse 395B 1190 WIEN Austria Mostra sulla mappa Costo totale Nessun dato Partecipanti (1) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto WINDLESHAW ENTERPRISES LIMITED Regno Unito Contributo UE Nessun dato Indirizzo Beech Green Lane Windleshaw House TN7 4DB Withyham Mostra sulla mappa Costo totale Nessun dato
